source
- Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD programNovo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…
- Four biotech firms secure Series B funding and open new hiring opportunitiesBiotech companies that closed Series B financing rounds this year are actively recruiting as they expand their operations. Atavistik Bio, based in Cambridge, Massachusetts, announced a $40 million…